Amoebiasis is an infection of the large intestine caused emptying has occurred; a time-based system can be by the protozoan parasite, Entamoeba histolytica.
employed for the targeted release 2 . Based on this Metronidazole and tinidazole are the most preferred concept, a modified pulsincap dosage form was drugs of choice for intestinal amoebiasis and these drugs developed. This capsule consisted of a water insoluble are to be delivered to the colon for their effective action body and a soluble cap. The drug formulation was against the trophozoites of E. histolytica that reside in the incorporated within the body, plugged with a polymer lumen of the caecum and large intestine and adhere to plug and the entire capsule was enteric coated to prevent the colonic mucus and epithelial layers. But the variable gastric emptying. The enteric coating prevents pharmacokinetic profile of metronidazole indicates that the disintegration of the soluble cap in the gastric fluid. On drug is absorbed completely after oral administration, reaching the small intestine the capsule loses its enteric reaching a concentration of about 10 µg/ml in plasma coating and the polymer plug inside the capsule swells to approximately 1 h after a single 500 mg dose.
create a lag phase that equals the small intestinal transit time. This plug ejects on swelling and releases the drug Conventional tablets of metronidazole provide minimal from the capsule in to the colon. Depending upon the amount of drug for local action in the colon, still resulting in the relief of amoebiasis, but with systemic side effects 1 . The various approaches available for colon specific drug delivery include coating with pH-dependent polymers, design of timed-release dosage forms, and the use of carriers that are degraded exclusively by colonic bacteria. The timed-release systems release their load after a predetermined time period of administration. In humans, studies have shown that, after leaving the stomach, a formulation arrives at the ileocaecal junction in about 6 h after administration. Thus once gastric *For correspondence E-mail: sindhuabraham_sara@rediffmail.com concentration of the polymer plug used, the time at which this occurs can be controlled 3 .
The rationale of this study is to design metronidazole pellets-loaded modified Pulsincap dosage form that can be targeted to the colon in a time-dependent manner. Colonic delivery of metronidazole could prevent systemic side effects and subsequently a lower dose of the drug may be sufficient to treat protozoal infections.
MATERIALS AND METHODS
Metronidazole, microcrystalline cellulose (Avicel PH102), carboxymethylcellulose sodium (SCMC), www.ijpsonline.com hydroxypropylmethylcellulose (HPMC) 10K and cellulose acetate phthalate (CAP) were obtained as gift samples from Eros Pharma Ltd., KAPL and Ce-Chem Pharmaceuticals, Bangalore. Sodium alginate was procured from S. D. Fine Chemicals Ltd., Mumbai. Guar gum was obtained as a gift sample from Juggat Pharma Ltd., Bangalore. All the other reagents were of pharmaceutical grade and were used as received.
Preparation of metronidazole pellets and formaldehyde-exposed hard gelatin capsules:
For In vitro release profile, dissolution studies were carried out for 12 h, for both the plain drug pellets and the Modified Pulsincap dosage form according to USP apparatus I (Basket) method. The dissolution media used were: Acidic buffer, pH 1.2 for 2 h (since the average gastric emptying time is 2 h), Phosphate buffer, pH 7.4 for 3 h (since the average small intestinal transit time is 3 h), Phosphate buffer, pH 6.8 buffer for subsequent hours (to simulate colonic fluid). The dissolution media was rotated at 100 rpm. Samples (5 ml) were withdrawn at specific time intervals and equal volume of media was replaced Metronidazole pellets were prepared using the extrusionimmediately. Withdrawn samples were then filtered, spheronization method 4 . The filler used was Avicel PH102.
suitably diluted and the amount of metronidazole Bodies of hard gelatin capsules (Size 0) were placed on a dissolved was determined by UV absorption at 277 nm 6 wire mesh. Formaldehyde (15%) was taken in to a (for pH 1.2 buffer) and 320 nm (for pH 7.4 buffer and pH dessicator and potassium permanganate was added to it until 6.8 buffer). The cumulative amount of drug released was vapors were produced. The wire mesh containing the calculated. bodies was then exposed to formaldehyde vapors. The reaction was carried out for 12 h 5 after which the bodies
RESULTS AND DISCUSSION
were removed and dried at 50° for 30 min to ensure completion of reaction between gelatin and formaldehyde Surface morphology studies revealed that the pellets were vapors. The bodies were then dried at room temperature discrete, spherical in shape and devoid of cracks ( fig. 1 ). to ensure removal of residual formaldehyde.
The pellets exhibited good flow properties as evident from Table 2 . When the capsules were subjected to Development of modified Pulsincap dosage form:
solubility studies in different buffers, the untreated caps Pellets equivalent to 150 mg of metronidazole were disintegrated within 10 min in all the media whereas the accurately weighed and filled into the treated bodies by hand filling. Capsules containing the drug pellets were 
Evaluation of metronidazole pellets:
Surface morphology of the pellets was studied using LEICA S440i scanning electron microscope after coating them with gold vapors. Morphological analysis was carried out at different magnifications. The Carr's index and angle of repose of the pellets were also determined. For disintegration studies, 10 capsules (with treated bodies and untreated caps) were randomly selected. These capsules were then subjected to disintegration studies at room temperatures in buffers of pH 1.2, 7.4 and 6.8. A single capsule was placed in the buffer solution and stirred for 24 h. The time taken for the capsule to disintegrate was noted. All the formulations were assayed to determine the drug content ( in three media, namely simulated gastric fluid (acidic buffer, pH 1.2) for the first 2 h, simulated small intestinal fluid (phosphate buffer pH 7.4) for 3 h and simulated colonic fluid (phosphate buffer pH 6.8) for the subsequent hours. The two pH buffer systems namely pH 7.4 and pH 6.8 were selected only to mimic the conditions in the small intestine and colon and they did not have www.ijpsonline.com
From the data presented in Table 3 , it is evident that the release of metronidazole from Modified Pulsincap is proportional to the concentration of hydrogel. Formulations F2 (30 mg guar gum), F5 (30 mg SCMC), F11 (30 mg sodium alginate) and F12 (40 mg sodium alginate) are suitable for colonic delivery of metronidazole as they could minimize drug release in the simulated small intestinal fluid and release major portion of the drug in the simulated colonic fluid, when compared to the other formulations. Therefore, the study proves that metronidazole can be successfully colon targeted by the use of a time-dependent modified Pulsincap formulation.
